Who is sponsoring NCT05073614?

NCT05073614 is sponsored by Sohag University.

What drugs are being tested in NCT05073614?

Interventions in NCT05073614: immunohistochemical detection of Heparanase in chronic gastritis.

What condition does NCT05073614 study?

NCT05073614 studies Chronic Gastritis.

Is NCT05073614 still recruiting?

NCT05073614 is currently completed. Last updated 4 February 2022.

Last reviewed 2022-02-04 · How we verify

NCT05073614

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Immunohistochemical Expression of Heparanase in Helicobacter Pylori-Associated Chronic Gastritis

Completed NA Last updated 4 February 2022

What this trial tests

NA trial testing immunohistochemical detection of Heparanase in chronic gastritis in Chronic Gastritis in 70 participants. Completed in 1 January 2022.

Timeline

1 July 2021

Primary endpoint
30 December 2021

1 January 2022

Quick facts

Lead sponsor	Sohag University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	70
Start date	1 July 2021
Primary completion	30 December 2021
Estimated completion	1 January 2022
Sites	1 location across Egypt

Drugs / interventions tested

immunohistochemical detection of Heparanase in chronic gastritis

Conditions studied

Chronic Gastritis — all drugs for Chronic Gastritis →

Sponsor

Sohag University

Who can join

Eligibility, any sex, with Chronic Gastritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of H.pylori may not be achieved in many patients with chronic gastritis. Termination of the inflammatory respose produced by h.pylori may be useful in management of difficult cases. Heparanase is a pro-inflammatory mediator. Blocking of heparanase may relief the symptoms of chronic gastritis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of Immunohistochemical Expression of Heparanase in <i>Helicobacter pylori</i>-Associated Chronic Gastritis.
Ahmed SFM, Abdelrahman MM, Mohammed MH. · · 2023 · PMID 37534373 · DOI 10.1177/2632010x231188937

Verify or expand the search:

Other Sohag University trials

Trials by the same sponsor.

NCT07119905 — Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patie · not yet recruiting
NCT07512219 — Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine · NA · not yet recruiting
NCT07519694 — Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery · NA · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
NCT07523386 — Compartive Study Between Cannulated Screw and Kws in Fixation of Distal Radius · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05073614 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sohag University
Last refreshed: 4 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05073614.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing